Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

154.27 +4.66 (+3.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,235,291
Open 147.99
Bid (Size) 152.00 (3)
Ask (Size) 155.54 (1)
Prev. Close 149.61
Today's Range 146.52 - 155.18
52wk Range 110.03 - 179.48
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above... 
Via StockStory
Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations
Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was... 
Via StockStory
Topics Artificial Intelligence

Performance

YTD
+2.8%
+2.8%
1 Month
+0.0%
+0.0%
3 Month
+16.9%
+16.9%
6 Month
+24.9%
+24.9%
1 Year
-11.3%
-11.3%

More News

Read More
Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide
Via Investor's Business Daily
Earnings Scheduled For October 30, 2025
Via Benzinga
Examining the Future: Biogen's Earnings Outlook
Via Benzinga
Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal
Via Stocktwits
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Via StockStory
Topics Artificial Intelligence
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
Via Benzinga
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
From Biogen Inc.
Via GlobeNewswire
3 Profitable Stocks We Steer Clear Of
Via StockStory
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
From Biogen Inc.
Via GlobeNewswire
ARPA-H Taps Former DARPA Innovator to Ignite High-Risk, High-Reward Health Tech Revolution
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround
Via The Motley Fool
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
Via Benzinga
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Via StockStory
Topics Government Stocks World Trade
1 Healthcare Stock to Research Further and 2 We Find Risky
Via StockStory
Topics Stocks
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
From Biogen Inc.
Via GlobeNewswire
Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)
Via StockStory
Topics Artificial Intelligence
UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know
Via StockStory
Topics Economy Government World Trade
7 Analysts Have This To Say About Biogen
Via Benzinga
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
1 Value Stock with Promising Prospects and 2 We Avoid
Via StockStory
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Via MarketMinute
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 154.27
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 10/31/25 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 22.49B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 22B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.